MIRA PHARMACEUTICALS, INC.
Close on Oct 19, 2026
- Market cap
- $26.98M
- P/E (TTM)
- –
- Dividend yield
- –
About Mira Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical development company focused on advancing novel oral therapeutics for neurologic, neuropsychiatric, metabolic, and addiction-related disorders. Its product candidate pipeline comprises Ketamir-2, an NMDA receptor modulator being evaluated for neuropathic and inflammatory pain indications such as chemotherapy-induced peripheral neuropathy; MIRA-55, an oral cannabinoid analog targeting inflammatory pain, anxiety, and cognitive impairment; and SKNY-1, an oral therapeutic candidate aimed at metabolic regulation and craving-related behaviors, including weight management and nicotine dependence. The company operates in the biotechnology and healthcare sector, developing therapies intended for patients suffering from acute and chronic medical conditions.
The company holds exclusive rights to its candidate pipeline across the United States, Canada, and Mexico. Preclinical evaluations and clinical trials are conducted under United States regulatory oversight, with manufacturing development supported by a contract development and manufacturing organization. The company maintains its principal executive offices in Miami, Florida.
Summary of the business section of Mira Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MIRA PHARMACEUTICALS, INC.
- Headquarters
- Miami, FL
- Address
- 1200 Brickell Avenue, Suite 1950 #1183 33131
- Phone
- (813) 369-5150
- Website
- mirapharmaceuticals.com
- Employees
- 2, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Florida
- Auditor
- SALBERG & COMPANY, P.A., Boca Raton, Florida
Stock & identifiers
- Ticker
- MIRA
- Exchange
- Nasdaq
- IPO date
- Aug 4, 2023
- Shares outstanding
- 42M, Aug 10, 2026
- Public float
- $15.95M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-1.33 reverse, Mar 28, 2025
- SEC CIK
- 1904286
- CUSIP
- 60458C104
- ISIN
- US60458C1045
- LEI
- 5493000N6HPDY7V7OR15
- EIN
- 85-3354547
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Erez Aminov | Chief Executive Officer, Director | 3,827,259 |
| Andriy Mushak | Chief Financial Officer | – |
| Alan Weichselbaum | Chief Financial Officer | – |
| Michelle Yanez | Chief Financial Officer | – |
| Giudice Matthew Paul Del | Director | – |
| Edward Clouston MacPherson | Director | – |
| Denil Nanji Shekhat | Director | 22,378 |
| Matthew Pratt Whalen | Director | – |
Employees
Headcount reported in annual reports
“As of March 28, 2026, we had two part time employees and various consultants providing support.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 31, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 30, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 8, 2025 | Merger vote | Definitive merger proxy statement |
| Apr 11, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Dec 20, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jul 12, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 4, 2023 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 31, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |
| May 2, 2023 | Name change | Name changed from Mira1a Therapeutics, Inc. to MIRA PHARMACEUTICALS, INC. |